A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...
Bengaluru: Researchers at the Indian Institute of Science (IISc) have uncovered how subtle variations in sugar molecules ...
Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback